Latest news with #HighnoonLaboratoriesLimited
Business Recorder
29-07-2025
- Business
- Business Recorder
Highnoon forges alliance with BD's Beximco
KARACHI: Highnoon Laboratories Limited, a prominent Pakistani pharmaceutical company, announces a significant strategic partnership with Beximco Pharmaceuticals Limited, a leading pharmaceutical firm based in Bangladesh. The collaboration aims to enhance the availability of specialised pharmaceutical products in Pakistan, focusing on critical therapeutic areas such as respiratory, diabetes, and cardiovascular diseases. The partnership was formalised through the signing of a Memorandum of Understanding (MoU) between the two companies. This alliance is set to introduce newer therapies, advanced dosage forms, and innovative drug delivery systems to the Pakistani market, promising improved ease of use and better clinical outcomes for patients, while simultaneously enhancing access to advanced medications. Beximco Pharmaceuti-cals Limited brings to the table state-of-the-art manufacturing facilities, which have received accreditation from stringent regulatory authorities across the globe, including the USA, Australia, the European Union, Canada, and Brazil. This robust accreditation underscores Beximco's commitment to quality and international standards. Highnoon Laboratories Limited, recognised as a recipient of Forbes Asia's 'Best Under A Billion' award in 2023, views this strategic alliance as a pivotal step. According to the disclosure made to the Pakistan Stock Exchange Limited, the company believes this partnership will not only benefit patients in Pakistan but also significantly contribute to the ongoing expansion of trade relations and economic cooperation between Pakistan and Bangladesh. The collaboration is expected to bring substantial advancements to Pakistan's healthcare sector, offering new hope and improved treatment options for patients suffering from high-burden diseases. Copyright Business Recorder, 2025
Business Recorder
29-07-2025
- Business
- Business Recorder
Highnoon Labs partners with Bangladesh's Beximco to target high-burden diseases in Pakistan
Highnoon Laboratories Limited (HINOON), a Pakistani pharmaceutical company, has announced a strategic partnership with Beximco Pharmaceuticals Limited, a leading Bangladesh-based drug manufacturer, to collaborate on the distribution and marketing of specialised pharmaceutical products in Pakistan. The listed pharmaceutical disclosed the development in its notice to the Pakistan Stock Exchange (PSX) on Tuesday. 'The company has entered into a strategic partnership with Beximco Pharmaceuticals Limited, a leading Bangladesh-based pharmaceutical company having state-of-the-art manufacturing facilities, accredited by the regulatory authorities of the USA, Australia, the European Union, Canada, and Brazil,' read the notice. HINOON shared that a memorandum of understanding (MoU) has been inked between the two companies to collaborate for the distribution and marketing of specialised pharmaceutical products in Pakistan, with the focus on high-burden therapeutic areas including respiratory, diabetes, and cardiovascular diseases. Bangladesh firm opens outlet in Karachi 'Through this partnership, the company will bring newer therapies, dosage forms and delivery systems for the ease of use and better clinical results for patients and improve access to the advanced medications. This strategic alliance will make a significant contribution to the recent expansion of trade relations and economic cooperation between Pakistan and Bangladesh,' read the notice. Beximco Pharmaceuticals Ltd. is an emerging generic drug player committed to providing access to affordable medicines. It currently focuses on building presence in many emerging and developed markets around the world. Meanwhile, Highnoon Laboratories Limited was incorporated in Pakistan as a private limited company in 1984 and was converted into a public limited company in 1995. The principal activity of the company is the manufacturing, import, sale and marketing of pharmaceutical and allied consumer products.
